Form 8-K NGM BIOPHARMACEUTICALS For: Feb 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NGM Biopharmaceuticals (NGM) PT Raised to $30 at Cowen
February 24, 2020 12:11 PM ESTCowen analyst Ritu Baral raised the price target on NGM Biopharmaceuticals (NASDAQ: NGM) to $30.00 (from $25.00) while maintaining an Outperform rating.
The analyst commented, "NGM presented topline biopsy data from Cohort 4 in their Ph2a. The data demonstrated impressive improvements in both fibrosis (38% vs 18% pbo)... More
